INTRODUCTION: Actual conservative oncological-treatment implies combined radio- (RT), chemo- (CT:cytostatics), thermo- (HT:hyperthermia) therapy: Efficacy depends essentially on vasomotor-reactions. Their biophysical-mechanisms are hardly investigated. Recent results related to summarized long-term investigations (2014-1970) are given.
METHOD: Vasomotor-activity of isolated helical-strips see ref.[1].
RESULTS (n=350): A.-Radiosensitivity of arteries&veins (human renal/ovarian/uterine; rat& guinea-pig&rabbit aorta/caval-vein/pulmonal-vessels) is very variable. X-rays-0.1-100Gy induce different kinds of ir-/reversible reactions. B.-Photosensitizers chlorophylline-derivatives/metalloporphyrine-complexes (Ag,Fe,Cu,Co) 1-10µg/ml strongly inhibit radiogenic reactions (but potentiate photogenic: UV-radiation-150W-Xenon-lamp-235-370nm; He-Ne-laser-632.8nm,10W). C.-X-rays inhibit EDRF (rat-aorta). D.-Hyperthermia (37-45°C) has relaxing-effects, radiogenic-contractions are potentiated by [Ca]-increase, hormones (nor-&adrenaline, prostaglandins) or abolished (45°C). E.-Drugs: AspirinR-indomethacin-theophylline-nifedipine antagonize radiogenic-contractions. F.-CT-cytostatics (adriblastin-bleomycin-colchicine-cis-Pt,etc. 0.1-50µg/ml) have also vasoconstrictor-effects (s.A).
CONCLUSION: Clarification of biophysical-mechanisms of oncotherapeutic vasomotor-reactions (A-F): Receptor or store-operated Ca-dependent-stretch-channels (Ca-entry by endothelin-1),etc. could lead to discovery of factors antagonizing radiogenic&thermo-induced vasomotor-reaction (drugs, microwave-irradiation supporting heat-shock-proteins,etc.), which decrease oncotherapeutic-efficacy: better oxygenation,etc. Also “radio-dynamic-therapy” & enlargement of Boron-neutron-capture-therapy(10B) (Gordon-Locher/USA) by porphyrins-implication is possible.
DEDICATION to support (2014-1980) of Nobel-Laureates/Hon. ICSD-members: Africa/N.MAHFOUZ, W.SOYINKA, Bishop TUTU, America-Asia/H.G.KHORANA/India-USA, Y.T.LEE/China, L.PAULING/USA, Europe/M.EIGEN/Germany, F.SANGER, Lord A.TODD/GB, B.SAMUELSON/Sweden, also Otto-HUG, R.WITTENZELLNER/GSF-Founder, Munich/Germany.
REFERENCES: Michailov,Neu,Welscher et-al.: [1] BIOPHYSICS-CHEMISTRY-PHARMACOPHYSIOLOGY: IUPAB-2011-Beijing (Int.Biophys.Congr.): Protein&Cell-Springer, S19-03:113-114/185-186/581-582 (Summary 12-IUPAB-Congr.2011-1975). Rad. Biophys. 1982:20,245-254, 1975:11,289-294, 1971:7,276-282. IUPAC-2013-Istanbul (World-Congr.Chem.): Abstract-Book 224&611&613&1526. Int.Congr.Proc.-IUPHAR: 2010-Copenhagen Basic&Clin.Pharm.&Tox. 17/S1,454-5/488-9. EUROTOX-2012-Stockholm Tox.Lett. 211/S:S211&212, 2011-Paris Tox. Letters 205S, S203/S298. IUPS 2009-Kyoto 22: J.Physiol.Sci.-59/S1:168&214&447-448. 2005-San-Diego 21:Faseb-J 19/4:139.4/351.21, 19/5:772.14/772.15.
[2] Clin. RADIOLOGY [2a] (IntSocRadiol) ISR-2010-Shanghai:AB:113/157; 2004-Montreal: AB:116/233/256; 1977-Rio-de-Janeiro AB:577 [2b] (IntSocIntraopRadiother) IORT-2012 Baveno/L.Maggiore, CD/ISIORT 2008-Madrid REV.CANCER 22/S:10-11/29-30; 2002-Aachen AB:10.2, 2000-Boston Proc.IORT 85/118/119, 1998-Pamplona RevMedUnivNAVARRA XLII/S:P-34/P-35/P-31, 1996/7-San-Francisco FrontRadiatThOncol BASEL:KARGER 31:22-35, 1994-Lyon Hepatoenter41:16, 1992-München Strahlenther 168:460 & IntraopRadiother, Essen:Vg"Blaue-Eule" 1993,27-39 [2c] Thermother 1995-Oxford-ESHO AB:54. [2d] Exp. RADIOLOGY: IARR-2011 all 11 congr. upto 1970-Evian, p564. [2e] ERRS-ESRB-1986 Pisa AB:H-12. 1987-IntJRadiobiol. 51:920 1981-Krakow164 1977-Liege,53&66 1971 Basko-Polje87 1970-München DtRöntgen-Congr (edO.HUG) THIEME Stuttgart:89-91/1972.
[3] STRAHLENTHER.-ONKOL. 1970:139,330-335, 1974:147,290-297&148,409-412, 1975:149,602-607, 1976:151:549-554, 1979:155/4:284-286, 1983: 159/7:448-451, 1989:165:860-5, 1991:167:311-8.
[4] PHOTO-BIOL&MED: (IntUnPh) IUPB/AIP-2009-Düsseldorf147-8, 192-195, 1996-Vienna307, 1992-Kyoto229, 1976-Rome204-5.